-- 据《日经新闻》周三报道，日本同意从阿联酋额外购买2000万桶原油，以应对霍尔木兹海峡附近海域的供应中断，并寻求其他替代供应路线。 该协议是在经济大臣赤泽亮生与阿联酋工业部长苏尔坦·贾比尔在阿布扎比举行会谈后达成的。报道称，赤泽亮生表示，他已请求阿联酋向日本增发原油。 根据2025年的消费水平计算，这批额外的原油大约可以满足日本八到九天的石油需求。报道称，部分原油预计将经由阿曼湾的富查伊拉港运输，从而避开霍尔木兹海峡。 日本约40%的原油进口来自阿联酋，随着中东局势日益紧张，日本一直在寻求其他供应渠道。报道还指出，东京上个月还从墨西哥获得了100万桶原油。 （市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源，但可能包含传闻和推测。准确性无法保证。）
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661